trial

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

NCTId NCT02970929
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 157 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2019-01-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
157 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2017-01-31
Primary completion
2019-01-29
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

30 total
Little Rock, United StatesPico Rivera, United StatesSan Diego, United StatesAtlanta, United StatesLake Charles, United StatesDallas, United StatesGyöngyös, HungaryGyula, HungaryBucharest, RomaniaBucharest, RomaniaCraiova, RomaniaIași, Romania

Linked catalysts

1
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects Wi — primary completion2019-01-29

Facts & assertions

4 sourced
Enrollment
157
Phase
PHASE2
Primary Completion Date
2019-01-29
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication